Auxora Versus Standard of Care For The Treatment of Severe or Critical COVID-19 Pneumonia: Results From A Randomized Controlled Trial

Joseph Miller

Henry Ford Health System

Charles Bruen

Regions Hospital, Health Partners

Michael Schnaus

Methodist Hospital

Jeffrey Zhang

Princeton Pharmatech

Sadia Ali

Methodist Hospital

April Lind

Methodist Hospital

Zachary Stoecker

Methodist Hospital

Kenneth Stauderman

CalciMedica, Inc

Sudarshan Hebbar (✉ sudarshan@calcimedica.com)

Research

Keywords: COVID-19 pneumonia, calcium release-activated calcium channel inhibitors, CRAC channel inhibitors, proinflammatory response, pulmonary endothelium, respiratory complications

Posted Date: July 30th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-42600/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on August 14th, 2020. See the published version at <https://doi.org/10.1186/s13054-020-03220-x>.

Abstract

BACKGROUND: Calcium release-activated calcium (CRAC) channel inhibitors stabilize the pulmonary endothelium and block proinflammatory cytokine release, potentially mitigating respiratory complications observed in patients with COVID-19. This study aimed to investigate the safety and efficacy of Auxora, a novel, intravenously administered CRAC channel inhibitor, in adults with severe or critical COVID-19 pneumonia

METHODS: A randomized, controlled, open-label study of Auxora was conducted in adults with severe or critical COVID-19 pneumonia. Patients were randomized 2:1 to receive three doses of once-daily Auxora versus standard of care (SOC) alone. The primary objective was to assess safety and tolerability of Auxora. Following FDA guidance, study enrollment was halted early to allow for transition to a randomized, blinded, placebo-controlled study.

RESULTS: In total, 17 patients with severe and three with critical COVID-19 pneumonia were randomized to Auxora and nine with severe and one with critical COVID-19 pneumonia to SOC. Similar proportions of patients receiving Auxora and SOC experienced ≥ 1 adverse event (75% versus 80%, respectively). Fewer patients receiving Auxora experienced serious adverse events versus SOC (30% versus 50%, respectively). Two patients (10%) receiving Auxora and two (20%) receiving SOC died in the 30 days after randomization. Among patients with severe COVID-19 pneumonia, median time to recovery with Auxora was five days versus 12 days with SOC; recovery rate ratio was 1.87 (95%CI, 0.72, 4.89). Invasive mechanical ventilation was needed in 18% of patients with severe COVID-19 pneumonia receiving Auxora versus 50% receiving SOC (absolute risk reduction=32%; 95%CI, -0.07, 0.71). Outcomes measured by an 8-point ordinal scale were significantly improved for patients receiving Auxora, especially for patients with a baseline $\text{PaO}_2/\text{FiO}_2=101\text{-}200$.

CONCLUSIONS: Auxora demonstrated a favorable safety profile in patients with severe or critical COVID-19 pneumonia and improved outcomes in patients with severe COVID-19 pneumonia. These results, however, are limited by the open-label study design and small patient population resulting from early cessation of enrollment in response to regulatory guidance. The impact of Auxora on respiratory complications in patients with severe COVID-19 pneumonia will be further assessed in a planned randomized, blinded, placebo-controlled study.

Trial registration: ClinicalTrials.gov, NCT04345614. Submitted 7April2020 - <https://clinicaltrials.gov/ct2/show/NCT04345614>

Background

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the disease COVID-19, was first identified in December 2019 and designated a global pandemic by the World Health Organization in February 2020.¹ The majority of COVID-19 cases are mild, but up to 20% of patients develop severe or critical pneumonia, manifested by hypoxemia or respiratory failure necessitating

mechanical ventilation, respectively.^{1,2} COVID-19 pneumonia presents with a constellation of symptoms including fever, cough, and dyspnea, with infiltrates usually noted on lung imaging.^{1,2} While the pathophysiology for COVID-19 pneumonia remains under investigation, there is an increasing body of literature to suggest a multifactorial lung injury and the important role of a hyperinflammatory state in its development.³⁻⁵ Among patients with COVID-19 pneumonia, viral infiltration has been shown to cause severe endothelial injury and diffuse alveolar damage.²⁻⁵ Furthermore, there appears to be an increase in proinflammatory cytokines leading to additional lung injury.²⁻⁵ Together, these factors contribute to clinical deterioration, the need for invasive mechanical ventilation, and, in a substantial proportion of patients, death.²⁻⁵

Evidence suggests that calcium release-activated calcium (CRAC) channels play a role in inflammation-induced injury of pulmonary endothelial cells, resulting in loss of alveolar-capillary barrier function and extravasation of fluid into the alveoli.⁶⁻⁹ CRAC channel activation is also linked to the production of proinflammatory cytokines associated with worsened outcomes in COVID-19.⁷⁻¹¹ Thus, inhibition of CRAC channels may be beneficial in preserving pulmonary endothelial integrity, reducing proinflammatory cytokine levels, and improving oxygenation in patients with COVID-19 pneumonia.^{8,11-14}

CM4620 is a potent and selective CRAC channel inhibitor.^{11-13,15} Preclinical work has demonstrated that in acute inflammatory conditions, CM4620 reduces inflammatory signals in the lung, protects tissues from calcium-induced damage and lowers serum and pulmonary proinflammatory cytokine levels.^{7,9,11,12} Auxora, the novel intravenously administered nanoemulsion formulation of CM4620, rapidly distributes to the lungs and blocks CRAC channel dependent cytokine release within hours of its administration.¹⁵ Based on these data and rationale, Auxora was investigated in patients with severe or critical COVID-19 pneumonia. The interim analyses presented here describe the safety of Auxora for all patients enrolled in the study; the efficacy analysis is limited to those with severe COVID-19 pneumonia.

Methods

Patient Selection

This Phase 2, randomized, controlled, open-label study was conducted across three centers in the United States (ClinicalTrials.gov number, NCT04345614). Patient enrolment took place from April 8, 2020 to May 13, 2020. Eligible patients were adults with a diagnosis of COVID-19 determined by reverse transcription polymerase chain reaction and pneumonia documented by chest imaging. In addition, patients were required to have ≥ 1 symptom consistent with COVID-19, such as fever, cough, sore throat, malaise, headache, muscle pain, dyspnea, confusion, or respiratory distress, and ≥ 1 clinical sign suggesting respiratory compromise, such as respiratory rate ≥ 30 breaths per minute, heart rate ≥ 125 bpm, $\text{SpO}_2 < 93\%$ on room air or requiring $> 2\text{L}$ oxygen by nasal cannula to maintain $\text{SpO}_2 \geq 93\%$, or $\text{PaO}_2/\text{FiO}_2 < 300$, imputed from pulse oximetry or determined by arterial blood gas.

Study Design

The initial study design included enrolment of 60 patients receiving low flow supplemental oxygen at screening into Arm A (severe COVID-19 pneumonia) and 60 patients receiving high flow supplemental oxygen through a high flow nasal cannula at screening into Arm B (critical COVID-19 pneumonia). In both arms, patients were randomly assigned in a 2:1 ratio to receive Auxora plus standard of care or standard of care alone; randomization was not center specific. Auxora was administered on three consecutive days as a 4-hour continuous intravenous infusion. The initial dose was 2.0 mg/kg (max 250 mg) and subsequent doses were 1.6 mg/kg (max 200 mg) at 24 and 48 hours. All patients received local standard of care, including anti-viral agents, but investigational therapies and immunosuppressive medications were not permitted. At the discretion of the site investigators, patients treated with either Auxora or standard of care alone were able to receive convalescent plasma if they required invasive mechanical ventilation.

After admission, patients were assessed daily for the first ten days and then every 48 hours until Day 28 or discharge, whichever occurred first. On Day 30, all patients were assessed for mortality. Discharged patients were contacted by phone. All adverse events (AEs) and serious adverse events (SAEs) were recorded during hospitalization. The SpO₂ and FiO₂ at the time of the study visit and the lowest SpO₂/FiO₂ ratio documented over the previous 24 hours were recorded daily. The patient's clinical status was also evaluated daily by assessing if the patient was alive, required invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), high flow supplemental oxygen or non-invasive ventilation, low flow supplemental oxygen, or other ongoing medical care in the previous 24 hours. The need for continued supplemental oxygen was also assessed at the time of discharge.

The trial protocol was approved by an institutional review board at each site and was overseen by an independent safety review committee (ISRC). Informed consent was obtained from either the patient or from the patient's legally authorized representative if the patient was unable to provide consent. The ISRC was scheduled to perform a review for each arm after the first 12 patients were dosed with Auxora and then again after 24 patients were dosed. The analysis plan called for a separate evaluation of the safety and efficacy of the two arms as enrolment rates were expected to differ. The ISRC conducted an initial review on May 3, 2020 after the first 12 patients in Arm A were dosed with Auxora. At that time, six patients had received standard of care in Arm A. The ISRC recommended continuing the trial without changes. The US Food and Drug Administration (FDA) was sent the interim efficacy data presented here in response to questions about the ISRC review. The FDA provided guidance on May 12, 2020, to limit further enrolment in the open-label study and transition to a randomized, blinded, placebo-controlled study, and as such, both Arms A and B ceased further enrolment.

Statistical Analysis

All analyses were conducted in the Intention to Treat population. The primary objective was to determine the safety and tolerability of Auxora for patients with severe and critical COVID-19 pneumonia. The

incidence, intensity, and relationship of AEs and SAEs, and the development of laboratory abnormalities that were clinically significant and required intervention were assessed. Mortality at Day 30 was evaluated as a safety outcome. For the purpose of safety and outcome analyses, patients from Arms A and B were analyzed together, comparing treatments with Auxora and standard of care with standard of care alone.

Efficacy outcome measures included recovery rate defined as the first day the patient satisfied criteria 6, 7, or 8 of the 8-point ordinal scale (Table 1). Additional efficacy outcome measures included the change in the 8-point ordinal scale over time, the proportion of patients requiring invasive mechanical ventilation, and a composite outcome of death or invasive mechanical ventilation.

Pre-specified efficacy analyses were performed on enrolled patients with severe COVID-19 pneumonia (Arm A) and in 3 subgroups of Arm A according to their baseline $\text{PaO}_2/\text{FiO}_2$ (1-100, 101-200, or ≥ 201). Baseline $\text{PaO}_2/\text{FiO}_2$ was defined as the lowest value in the 24 hours prior to screening. The PaO_2 was imputed from the SpO_2 using a published table based on Ellis's inversion of the Severinghaus equation.^{16,17}

Results

Patients

At the time of cessation, 30 patients had been enrolled into the study. Of the 26 patients in Arm A, 17 were randomized to treatment with Auxora and nine to standard of care alone. Four patients were enrolled into Arm B: three to treatment with Auxora and one to standard of care alone (Figure 1). Across both arms, 18 patients (90%) received three doses of Auxora as assigned. One patient in Arm A received only one Auxora dose due to rapid improvement and early discharge. One patient in Arm B refused the third dose of Auxora. One patient in Arm B, who received all three doses, was transferred after 120 hours to another institution; their outcome was followed by the initial study team. In the standard of care group of Arm A, one patient withdrew from the study at 96 hours after being made Do Not Intubate (DNI) because of declining respiratory status. This patient was not included in the intubation analysis (Figure 1). All patients who did not die in the hospital completed the Day 30 assessment.

Baseline demographics were balanced across the Auxora and standard of care groups in Arm A (Table 2), but more patients in the Auxora group had diabetes (47%) than in the standard of care group (22%). The median time (min, max) from symptom onset to randomization was nine (4, 34) days in the Auxora group and seven (4, 11) days in the standard of care group. The baseline mean imputed $\text{PaO}_2/\text{FiO}_2$ was 178 ± 74 in the Auxora group and 168 ± 78 in the standard of care group. In Arm B, baseline characteristics were more variable due to the small sample size (Table 1). Individual patient listings for Arm A are presented in the supplementary appendix Figure S1.

Fewer patients randomized to Auxora versus standard of care received steroids (47% versus 78%) or remdesivir (18% versus 33%) during the course of the study. Convalescent plasma was administered to 2 patients randomized to Auxora, while it was administered in all 4 patients randomized to standard of care who needed mechanical ventilation.

Safety Outcomes

Across both arms, 15 patients (75%) receiving Auxora had ≥ 1 AE and six patients (30%) had ≥ 1 SAE. Site investigators judged three AEs, each occurring in three different patients, as being related to the administration of Auxora: an episode of itching, an increase in alkaline phosphate, and a rash. They were all were considered mild by the investigators and resolved. None of the reported SAEs were determined to be related to the administration of Auxora. Among patients receiving standard of care, eight (80%) had ≥ 1 AE and five (50%) had ≥ 1 SAE. There was no difference in AEs related to infections in the Auxora group when compared to standard of care (30% in each group).

Two patients (10%) treated with Auxora and two patients (20%) receiving standard of care died while hospitalized between ten and 17 days after randomization (supplementary appendix Figure S1). There were no deaths in the 30 days after randomization for patients who were discharged from the hospital. Both patients in the Auxora group and one patient in the standard of care group died while receiving invasive mechanical ventilation. The other patient receiving standard of care who died had been made DNI.

Efficacy Outcomes

Patients with severe COVID-19 pneumonia (Arm A) treated with Auxora had a shorter median time to recovery (five days) than patients treated with standard of care (12 days); the recovery rate ratio was 1.87 (95% confidence interval [CI], 0.72 to 4.89; Figure 2). In addition, three of 17 patients treated with Auxora (18%) were intubated compared to four of eight (50%) assigned to standard of care (95% CI, -0.07 to 0.71). The reduction was most pronounced in patients with a baseline $\text{PaO}_2/\text{FiO}_2$ between 101-200, in which only one of six patients (17%) treated with Auxora required intubation compared to three of four patients (75%) assigned to standard of care. No patients receiving Auxora or standard of care with a baseline $\text{PaO}_2/\text{FiO}_2 > 200$ required invasive mechanical ventilation. A composite endpoint of death or invasive mechanical ventilation occurred less frequently in patients treated with Auxora (18%) compared to those assigned to standard of care (56%) with a hazard ratio of 0.23 (95% CI, 0.05 to 0.96; $P < 0.05$; Figure 3).

Clinical improvement, as measured by the mean of an 8-point ordinal scale, was greater in the Auxora group starting at Day 4, reaching statistical significance on Day 6, and remained significant from Day 9 through Day 12 ($P < 0.05$; Figure 4). On Day 4, the odds ratio for clinical deterioration on the 8-point ordinal scale for the Auxora group compared to the standard of care group was 0.21 (95% CI, 0.04 to 0.098; $P < 0.05$). The clinical improvement was most pronounced in patients with a baseline $\text{PaO}_2/\text{FiO}_2$ between

101-200, with the difference in means reaching statistical significance at Day 7; this was maintained through Day 12 ($P < 0.05$; Figure 5).

Discussion

In this Phase 2, open-label, randomized, multicenter study of patients with severe or critical COVID-19 pneumonia, Auxora, a novel, intravenously administered CRAC channel inhibitor, demonstrated a potential therapeutic benefit in mitigating the respiratory complications of COVID-19. At the recommendation of the US FDA, this study was halted prior to completion of the originally planned 120 patients in order to transition to a randomized, placebo-controlled, double-blind study.

CRAC channel activation in the pulmonary endothelium is linked to the breakdown of the alveolar-capillary barrier.⁷⁻⁹ CRAC channel activation also initiates the production and release of proinflammatory cytokines from immune cells.^{10,11} The resulting development of pulmonary edema, hypoxemia, and ultimately ARDS contributes to the significant morbidity and mortality seen in COVID-19 pneumonia, particularly in those who eventually require invasive mechanical ventilation.^{14,18} As demonstrated in animal models, inhibition of CRAC channels stabilizes pulmonary endothelial cells, blocks the release of proinflammatory cytokines and decreases vascular inflammation and permeability.^{7,9,14} Given the direct effects on the pulmonary endothelium and the indirect effects on proinflammatory cytokine production, Auxora may be an attractive therapy for the management of patients with severe COVID-19 pneumonia.⁷⁻⁹ Auxora has also demonstrated rapid distribution to the lungs, resulting in a fast onset of action that is reversible in 24 to 48 hours (unpublished observations).

The data available at the time of study termination indicate an encouraging safety profile for Auxora, with no increase in the proportion of patients experiencing AEs or SAEs when compared with standard of care. Furthermore, while the sample size was small, patients receiving Auxora appeared to have a more favorable clinical course than patients receiving standard of care as reflected by the rapid time to recovery, the decreased need for steroids, remdesivir, convalescent plasma, or invasive mechanical ventilation, and greater improvement in clinical outcomes as documented by the difference in 8-point ordinal scale. Analysis of the ordinal scale over time also suggested greater odds of improvement in patients treated with Auxora beginning on Day four, with the most pronounced clinical benefit in patients with a PaO₂/FiO₂ ratio between 101-200. These efficacy signals will need to be confirmed in a larger, double-blind, placebo-controlled study.

The ideal timing and duration of intervention in the course of COVID-19 pneumonia remains unknown.¹⁹ There are some concerns that premature immunomodulation may inhibit host anti-viral immunity and delay viral clearance, while delaying immunomodulation may prove futile if acute pulmonary injury is advanced. The PaO₂/FiO₂ ratio, imputed from the SpO₂/FiO₂, could serve as a simple means of determining both the optimal timing of intervention and the patients most likely to benefit^{16,17}; it should be incorporated into other studies of therapies for COVID-19. Currently, patients are only being

categorized by the receipt of either low flow supplemental oxygen or high flow supplemental oxygen, but this approach may not capture the severity of lung injury, may mask patients who are likely to respond to treatment and is limited by substantial inter-institution variations in practice.

Our findings, and those from recent remdesivir and RECOVERY trials, raise consideration for a two-pronged approach for the treatment of COVID-19 pneumonia.^{19,20} Preliminary results of remdesivir for the treatment of COVID-19 demonstrated reduced time to recovery, but treatment alone with an antiviral therapy is unlikely to be sufficient in improving outcomes.¹⁹ It may be possible, however, to improve patient outcomes by combining an antiviral treatment with immunomodulation to address the inflammatory response. Results from the RECOVERY trial demonstrated that after up to 10 days of receiving oral or intravenous dexamethasone once-daily, the 28-day mortality was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%, respectively) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%, respectively).²⁰ The 28-day mortality rates in the RECOVERY trial for patients receiving low flow supplemental oxygen versus high flow supplemental oxygen were not presented. Finally, there was a non-significant decrease in a composite outcome of death or invasive mechanical ventilation among patients not receiving invasive mechanical ventilation at randomization who were treated with dexamethasone compared to those treated with usual care (25.6% vs. 27.3%, respectively).²⁰ As Auxora is associated with a rapid onset of action and a rapid cessation of action, it appears to work quickly to reduce proinflammatory cytokines while preserving pulmonary endothelial integrity, without excessive immunosuppression¹⁵ but further research is needed in patients with severe COVID-19 pneumonia. Coupled with the low 28-day mortality rate (10%) presented here, Auxora may allow for improved patient outcomes when used in combination with dexamethasone. Additional clinical trials are needed to understand the effect of these combinations of therapy.

The interpretation of the results of this study is limited by the open-label design and small sample size. Additionally, the significant imbalances in age and medical comorbidities between the three patients receiving Auxora and one patient receiving standard of care in Arm B prevented a meaningful direct comparison between the two groups with critical COVID-19 pneumonia. It was observed that the proportion of patients treated with Auxora who had diabetes, a co-morbidity associated with poorer outcome in COVID-19, was double that for patients receiving standard of care alone. Manufacturing and administration of a placebo was sacrificed given the need to initiate the study rapidly during the global pandemic with associated constraints on healthcare resources. These constraints, including adequate personal protective equipment, also limited the ability of research teams to obtain research-specific cytokine levels, which if obtained, may have further supported the mechanisms of Auxora.

Conclusions

In this preliminary, Phase 2 study of the novel CRAC inhibitor, Auxora, the observed favorable safety profile and efficacy signals when compared to standard of care support the need for further investigation

in a large, double-blind, placebo-controlled trial in patients with severe COVID-19 pneumonia. In addition, these results suggest the potential for the clinical development of Auxora for the treatment of other etiologies of acute respiratory distress syndrome. A randomized, placebo-controlled, double-blind study will soon be underway to test the efficacy of Auxora in combination with local standard of care, likely remdesivir and/or dexamethasone, for the management of patients with severe COVID-19 pneumonia.

Abbreviations

AEs, adverse events

CRAC, calcium release-activated calcium channels

DNI. Do not intubate

ECMO, extracorporeal membrane oxygenation

FDA, Food and Drug Administration

ISRC, independent safety review committee

SAEs, serious adverse events

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

Declarations

Ethics approval and consent to participate

The trial protocol was approved by an institutional review board at each site and was overseen by an ISRC. The trial was conducted in accordance with the guiding principles of the Declaration of Helsinki and was approved by the local institutional review boards. Informed consent was obtained from either the patient or from the patient's legally authorized representative if the patient was unable to provide consent. This trial is registered at ClinicalTrials.gov number, NCT04345614.

Consent for publication

Not applicable

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to the Clinical Study Report being finalized but will be available from the corresponding author on reasonable request at a later time

Competing interests

JM reports grants from CalciMedica, Inc. during the conduct of the study; and grants from CalciMedica, Inc. and Abbott Labs outside of the present work. JZ reports personal fees from CalciMedica, Inc. related to the statistical analysis incorporated in the present work. KS and SH are employees of, and hold stock in, CalciMedica, Inc. CB, MS, SA, AL, ZS declare no competing interests. The authors neither received payment from CalciMedica, Inc. for participation as investigators in the study, nor did they receive payment for the development of the present manuscript.

Funding

This study was funded by CalciMedica, Inc. (La Jolla, CA, USA). The study was designed by the funder (CalciMedica, Inc., La Jolla, CA, USA) with input from the lead investigators (JM and CB). The funder compiled and analyzed the study data and interpreted data in collaboration with all authors. All authors had full access to all the data in the study and provided input on the analyses before and during writing of the report and take responsibility for the integrity of the data and the accuracy of the data analysis. The corresponding author wrote the first draft of the report and the funder commissioned medical writing assistance from Sarah Odeh (San Francisco, CA, USA) to support subsequent drafts under the direction of all authors. All authors reviewed and revised each draft and approved the final submitted version. The corresponding author had final responsibility for the decision to submit for publication.

Authors' contributions

JM, CB, JZ, KS, and SH were involved in the study design and protocol development. All authors were involved in this clinical trial, vouch for the adherence of the trial to the protocol, for the accuracy of the data, and for the complete reporting of adverse events. JM and CB contributed equally to this article. JZ conducted the statistical analysis. All authors reviewed, revised, and approved the final version of the manuscript.

Acknowledgements

This study was funded by CalciMedica, Inc. (La Jolla, CA, USA). We thank the study participants and the Investigators and research teams who contributed to the study (supplementary appendix). Medical writing assistance was provided by Sarah Odeh (San Francisco, CA, USA), funded by CalciMedica, Inc.

References

1. Huang C, Wang Y, Li X, Zhao J, Hu Y, Zhang L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
2. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020; doi:10.1056/NEJMcp2009575.
3. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020; doi:10.1056/NEJMoa2015432.

4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395:1033-34.
5. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. 2020; doi:10.1001/jamainternmed.2020.0994.
6. Vadász I, Sznajder JI. Gas exchange disturbances regulate alveolar fluid clearance during acute lung injury. *Front Immunol*. 2017;8:757.
7. Gandhirajan RK, Meng S, Chandramoorthy HC, Mallilankaraman K, Mancarella S, Gao H, et al. Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. *J Clin Invest*. 2013;123(3):887-902.
8. Menendez JA. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19. *Aging*. 2020;12(10):8760-65.
9. Wang G, Zhang J, Xu C, Han X, Gao Y, Chen H. Inhibition of SOCs attenuates acute lung injury induced by severe acute pancreatitis in rats and PMVECs injury induced by lipopolysaccharide. *Inflam*. 2016;39(3):1049-58.
10. Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. *Annu Rev Immunol*. 2015;33:291-353.
11. Waldron RT, Chen Y, Pham H, Go A, Su HY, Hu C, et al. The Orai Ca(2+) channel inhibitor CM4620 targets both parenchymal and immune cells to reduce inflammation in experimental acute pancreatitis. *J Physiol*. 2019;597(12):3085-105.
12. Wen L, Voronina S, Javed MA, Awais M, Szatmary P, Iatawiec D, et al. Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models. *Gastroenterol*. 2015;149(2):481-92.e7.
13. Stauderman KA. CRAC channels as targets for drug discovery and development. *Cell Calcium*. 2018;74:147-59.
14. Seeley EJ, Rosenberg P, Matthay MA. Calcium flux and endothelial dysfunction during acute lung injury: A STIMulating target for therapy. *J Clin Invest* 2013;123(3):1015-18.
15. Stauderman K, Miller J, Chaudhry K, et al. Pharmacodynamic (PD)/pharmacokinetic (PK) study of CM4620 injectable emulsion in patients with acute pancreatitis. *Pancreas*. 2019;10:1401-564.
16. Brown SM, Grissom CK, Moss M, Rice TW, Schoenfeld D, Hou PC, et al. Nonlinear imputation of Pao2/Fio2 from Spo2/Fio2 among patients with acute respiratory distress syndrome. *Chest*. 2016;150(2):307-13.
17. Brown SM, Duggal A, Hou PC, Tidswell M, Khan A, Exline M, et al. Non-linear imputation of PaO2/FIO2 from SpO2/FIO2 among mechanically ventilated patients in the intensive care unit: a prospective, observational study. *Crit Care Med*. 2017;45(8):1317-24.
18. Tang S, Wu S, Peng C, Chu SJ, Wu CP, Perng WC, et al. Calcium release-activated calcium channel inhibitor, BTP2, attenuates ventilator-induced lung injury in rats. *Am J Respir Crit Care Med*. 2019;199:A1159.

19. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020; doi: 10.1056/NEJMoa2007764.

20. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020; doi: 10.1056/NEJMoa2021436.

Tables

Table 1. 8-Point Ordinal Scale.

Scale	Description
1	Death
2	Hospitalized, requiring invasive mechanical ventilation or ECMO
3	Hospitalized, requiring noninvasive mechanical ventilation or high flow supplemental oxygen
4	Hospitalized, requiring low flow supplemental oxygen
5	Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care
6	Hospitalized, not requiring supplemental oxygen or ongoing medical care
7	Discharged, requiring supplemental oxygen
8	Discharged, not requiring supplemental oxygen

Efficacy outcome measured with the 8-point ordinal scale included recovery rate defined as the first day the patient satisfied criteria 6, 7, or 8 and change in the 8-point ordinal scale over time. ECMO, Extracorporeal membrane oxygenation

Table 2. Baseline demographics and clinical characteristics.

	Arm A*		Arm B†	
	Auxora (n=17)	SOC (n=9)	Auxora (n=3)	SOC (n=1)
Age, years (mean±SD)	59±12	61±13	64±14	36±NA
Median BMI, kg/m ² (min, max)	30 (25, 79)	30 (23, 49)	23 (18, 36)	34
Male sex, n (%)	7 (41)	5 (56)	1 (33)	1 (100)
Ethnicity, n (%)				
White	8 (47)	5 (56)	1 (33)	0
Black or African American	7 (41)	3 (33)	1 (33)	1 (100)
Asian	0	1 (11)	1 (33)	0
Other/Multiple	2 (12)	0	0	0
Hispanic or Latino, n (%)	2 (12)	1 (11)	0	0
Diabetes, n (%)	8 (47)	2 (22)	2 (67)	0 (0)
Hypertension, n (%)	8 (47)	4 (44)	2 (67)	0 (0)
Median time from onset of symptoms to randomization, days (min, max)	9 (4, 34)	7 (4, 11)	11 (8, 17)	13
Ferritin, ng/mL (mean±SD)	709±553	772±742	1776±722	2151±NA
CRP, mg/dL (mean±SD)	10±7	12±6	14±11	9±NA
PaO ₂ /FiO ₂ (mean±SD)	178±74	168±78	106±45	87±NA
PaO ₂ /FiO ₂ ≥201	7 (41)	3 (33)	0	0
PaO ₂ /FiO ₂ 101-200	6 (35)	4 (44)	2 (67)	0
PaO ₂ /FiO ₂ ≤100	4 (24)	2 (22)	1 (33)	1 (100)
PaO ₂ /FiO ₂ 101-200	867±712	910±1090	1637±963	NA
Ferritin ng/mL (mean±SD)				
PaO ₂ /FiO ₂ 101-200	11±5	13±9	16±15	NA
CRP mg/dL (mean±SD)				

Baseline demographics were balanced across the Auxora and standard of care groups in Arm A. In Arm B, baseline characteristics were more variable due to the small sample size. ^{*}Patients in Arm A included those who were receiving low flow supplemental oxygen at screening and were defined by regulatory guidance as having severe COVID-19 pneumonia; [†]Patients in Arm B were defined by regulatory guidelines as having critical COVID-19 pneumonia. NA, not available; SOC, standard of care.

Figures

Figure 1

Patient Enrolment and Randomization. One patient in Arm A received only 1 Auxora dose due to rapid improvement and early discharge and 1 patient in Arm B refused the third dose of Auxora. One patient in Arm B, who received all 3 doses, was transferred after 120 hours to another institution. In the standard of care group of Arm A, 1 patient withdrew from the study at 96 hours after being made Do Not Intubate (DNI) because of declining respiratory status.

Figure 2

Recovery Rate Among Patients with Severe COVID-19 Pneumonia. Recovery rate defined as the first day the patient satisfied criteria 6, 7, or 8 of the 8-point ordinal scale. Patients receiving Auxora had a shorter median time to recovery (5 days) than patients treated with standard of care (12 days); recovery rate ratio was 1.87 (95% CI, 0.72 to 4.89). Patients with severe COVID-19 pneumonia were receiving low flow supplemental oxygen (Arm A).

Figure 3

Percentage of Patients with Severe COVID-19 Pneumonia Reaching Composite Endpoint. The composite endpoint was defined as needing invasive mechanical ventilation or death in the 30 days after randomization. Hazard ratio was 0.23 (95% CI, 0.05 to 0.96; $P < 0.05$). Patients with severe COVID-19 pneumonia were receiving low flow supplemental oxygen (Arm A).

Figure 4

8-Point Ordinal Scale Over Time in Patients with Severe COVID-19 Pneumonia. Mean difference was statistically significant for Auxora (n=17) when compared with standard of care (n=9) at Day 6 and Days 9 through 12 (*P<0.05 versus standard of care). Patients with severe COVID-19 pneumonia were receiving low flow supplemental oxygen (Arm A).

Figure 5

8-Point Ordinal Scale in Patients with Severe COVID-19 Pneumonia with PaO₂/FiO₂ Between 101-200. Mean difference was statistically significant from Day 7 through Day 12 for patients receiving Auxora (n=6) compared with those receiving standard of care (n=4; *P<0.05 versus standard of care). Patients with severe COVID-19 pneumonia were receiving low flow supplemental oxygen (Arm A).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [QWBALungTimeCourse.pdf](#)
- [SupplementaryAppendixAuxoraManuscript21Jun2020.docx](#)
- [AuxoraManuscriptAbstractFig22Jul2020.pdf.pdf](#)
- [CM4620204SAPFinalv12020611clean.pdf](#)
- [CM4620204COVID19protocolv30final.pdf](#)